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Objective: This study aimed to reach consensus among professional experts on patient
information provision and support regarding sexual rehabilitation and vaginal dilator use
after radiotherapy (RT) for gynecological cancers.
Methods: A 3-round online Delphi study was conducted among 10 radiation oncologists,
10 gynecologic oncologists, and 10 oncology nurses from 12 gynecological cancer centers
providing RT for gynecological tumors. We assessed the desired content and provider of
instructions and patient support regarding sexuality and vaginal dilator use. Responses were
measured on a 7-point scale varying from ‘‘totally disagree’’ to ‘‘totally agree.’’ Consensus
was reached when 70% of participants’ answers fell within 2 scale categories with an
interquartile range less than or equal to 1.
Results: The panel agreed that information about sexual rehabilitation using vaginal di-
lators should be provided by radiation oncologists before treatment. Information should
always be provided to sexually active cervical and vaginal cancer patients younger than 70
years. Tailored information was recommended for vulvar and endometrial cancer patients,
patients older than 70 years, and sexually inactive patients. Preferably, specifically trained
oncology nurses should give psychological and practical support. Participants recom-
mended vaginal dilation to prevent vaginal adhesions, tightening, and shortening. The panel
advised to start dilation around 4 weeks after treatment to perform dilation 2 to 3 times a
week for 1 to 3 minutes and to continue dilation for 9 to 12 months. Plastic dilator sets were
considered the most suitable type of dilator.
Conclusions: Consensus was reached on patient information provision and support during
sexual rehabilitation after RT for gynecological cancers. Results were used to develop a
sexual rehabilitation intervention.
Key Words: Gynecological cancer, Pelvic radiotherapy, Sexual rehabilitation, Vaginal
dilator use, Delphi method
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In the Netherlands, each year, 4500 women are diagnosedwith gynecological cancer,1 among which 1900 are diag-
nosed with endometrial cancers, 750 are diagnosed with
cervical cancers, and 60 are diagnosed with vaginal cancers.
About 35% of these women are treated with pelvic radio-
therapy (RT), either as primary or postsurgical treatment.2
Treatment for gynecological cancer may cause physical and
psychological adverse effects that interfere with the women’s
sexuality. Reported sexual problems among gynecological
cancer survivors are tightened and shortened vagina, dimin-
ished lubrication, dyspareunia, postcoital bleeding, and loss
of sexual desire, enjoyment, and satisfaction.3Y7 Most studies
agreed that the negative effect of gynecological cancer treat-
ment on sexual functioning was more pronounced when
treatment included RT, compared with surgery alone.8Y10 The
negative effect of RT is attributed to decreased lubrication,
shortening, and tightening of the vagina as a result of forma-
tion of fibrosis.10,11
Few studies investigated the effect of the regular use
of vaginal dilators on the development or prevention of vagi-
nal stenosis after treatment with RT. These studies showed
that regular vaginal dilator use is associated with less vagi-
nal shortening and/or tightening.12Y14 It is not clear how
the (changes in) vaginal dimensions were assessed in these
studies nor what the cause-and-effect relationship was be-
tween dilator use and the vaginal measurements. Although
more empirical evidence is needed,15 in clinical practice, reg-
ular dilator use is found to reduce the risk of shortening and/or
tightening due to adhesions and fibrosis. Dilator use is there-
fore advocated in many guidelines and reviews.16Y18
It is important to provide consistent and uniform
evidence-based counseling regarding when and how dilators
should be used.19Y21 In 2 survey studies from the United
Kingdom and Australia,22,23 there was consensus among pro-
fessionals that women undergoing pelvic RT for gynecolog-
ical malignancies should receive information about vaginal
dilation.22 In addition, professionals recommended to insert
a vaginal dilator during 5 to 10 minutes.22,23 Other recom-
mendations were inconsistent.22,23 No consensus existed re-
garding the most appropriate time interval after RT, the
frequency and duration of dilator use, dilator sizes offered,
insertion techniques, or the appropriateness of dilator use
among sexually inactive patients.22,23 Moreover, there was no
consensus on the content of instructions regarding patients’
sexual rehabilitation.
There is a clear need for consensus on all of these
aspects to further investigate the efficacy of a standardized
procedure of sexual rehabilitation and dilator use after RT.
Consensus is needed specifically on which specific gyneco-
logical cancer patients should receive information about
sexual rehabilitation and dilator use; what type of health
care provider should provide this information, counseling,
and support; and what should be the practical guidelines for
use of vaginal dilation.
The Delphi method proved to be an anonymous and
economic tool to reach consensus on best practice issues
in health care settings.24Y28 At first, a questionnaire ad-
dressing the opinion of an expert panel is assessed. Then a
second questionnaire is developed that is based on the first
questionnaire without the statements on which consensus
was reached. It is offered to the panel containing anonymous
feedback on the panels’ agreement. This encourages the panel
to reconsider their first response to the statements.
This study used the Delphi method and aimed to de-
termine clear recommendations on the content and proce-
dures of patient information provision and support regarding
sexual rehabilitation and vaginal dilator use after RT for
gynecological cancers. This was done conducting a 3-round
online Delphi study among recognized gynecologic oncolo-
gy professionals from different cancer centers and with var-
ious areas of clinical expertise.
MATERIALS AND METHODS
Participants
Eligible participants were radiation oncologists, gyne-
cologic oncologists, and oncology nurses, with recognized
clinical expertise in the treatment of gynecological cancer
patients receiving pelvic RT and expert knowledge on vagi-
nal dilation in this population. It was expected that 30 par-
ticipants, representing all Dutch gynecological cancer centers
and each of the 3 specialisms equally, would create a hetero-
geneous and representative panel.25Y28
Clinicians who participated in the Dutch gynecolog-
ical cancer network received an invitation e-mail, together
with a brochure explaining the study content and the Delphi
method, and an online informed consent form. Nonresponders
were approached by phone 1 week later. Before enrolment, it
was ascertained that participants had the intention to com-
plete all rounds of the study and had access to the Internet.
At the conclusion of the study, the participants received a
20-euro (ÈUS $27) gift voucher as a token of appreciation.
The study was approved by the Leiden University Medical
Center Medical ethics committee.
Questionnaire
The questionnaire consisted of statements and ques-
tions addressing participants’ opinions on 7 different categories
(Table 1). The questionnaire was developed based on litera-
ture on sexuality and vaginal dilation after pelvic RT19Y23,29
and previous in-depth interviews with professionals involved
in gynecological cancer treatment. Items were pilot-tested on
comprehensibility among 5 experienced researchers in the field
of gynecologic oncology and/or conducting Delphi studies.
Answers were measured using a 7-point Likert scales varying
from 1 (totally disagree) to 7 (totally agree) (n = 53), single-
choice (n = 8), and multiple-choice questions (n = 6). The
questionnaire also consisted of items measuring demographic
and work-related characteristics (eg, age and the years of ex-
perience in the field).
The Delphi Process
The present Delphi method was based on a frequently
published standard design.24Y28 The questionnaire elicited
responses in 3 rounds. After each round, the degree of con-
sensus was calculated. In case no consensus was reached on
an item, the group response was fed back to the participants
Bakker et al International Journal of Gynecological Cancer & Volume 24, Number 8, October 2014
1500 * 2014 IGCS and ESGO
Copyright © 2014 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
in the next round. Participants were asked to comment on
their answers in case it differed from the group response.
Items on which no consensus was reached, and that, according
to the comments by participants, seemed to be unclear were
adapted.
The degree of consensus on the 6 multiple-choice
questions that were used in round 1 could not be calculated.
Therefore, the multiple-choice questions were not counted
as part of the total number of items in round 1 and reformu-
lated as 25 Likert scale statements in the next round.
An online Delphi study was conducted to allow anon-
ymous inclusion of professionals across diverse centers and
expertise and avoid that a specific expert might dominate
the consensus process. Participants were asked to fill in each
questionnaire within 2 weeks. Nonresponders were sent a re-
minder by e-mail and, if necessary, received a subsequent
phone call after 1 week.
Consensus
It was decided beforehand that consensus was reached
when at least 70% of participants’ answers fell within the 2
lowest or highest answer categories on a Likert scale or within
1 category on a single-choice or multiple-choice question. In
addition, to reach consensus, an interquartile range (IQR) of
less than or equal to 1 was required. An IQR is a measure
of statistical dispersion representing the distance between
the 25th and the 75th percentile. A smaller IQR signifies a
large consensus, and an IQR less than or equal to 1 represents
good consensus on a 7-point Likert scale.27,28 When the de-
gree to which consensus was reached differed between the
3 specialisms, this will be reported.
Statistical Analyses
Descriptive statistics (percentages and IQRs) were
calculated to measure consensus. The group response on
items on which no consensus was reached was fed back to the
participants in round 2 by stating the median and in round 3 by
stating the median together with the modus. All statistical




Thirty-two clinicians were approached, of which 30
agreed to participate with a mean age of 48 years (see Fig. 1
for more information on the Delphi panel characteristics).
Experts from 3 different disciplines and all 12 gynecologi-
cal cancer centers in the Netherlands were included. Twenty-
seven participants had more than 5 years of experience within
the field of gynecologic oncology (90%), and 24 participants
regularly or often gave patients sexological support (80%). All
participants (100%) completed the 3 rounds.
Results
The specific results of the consensus rounds are shown
in Supplemental Digital Contents 1 and 2, which illustrate
all items that reached consensus (in round 1, 2, and 3) and
all items that did not reach consensus, respectively (available
at http://links.lww.com/IGC/A230 and http://links.lww.com/
IGC/A231).
Consensus Round 1
Consensus was reached for 22 of 50 items in round 1
(44%; Supplemental Digital Content 1, http://links.lww.com/
IGC/A230). After round 1, 8 items were formulated differ-
ently based on comments by participants. Furthermore, 1 item
was removed from the questionnaire because this question was
not specific enough.
The degree with which consensus was reached was
equal between the 3 professional groups except for 1 item.
The gynecologic oncologists reached the consensus that it is
TABLE 1. Description of the 7-item categories used in the questionnaire
Item Category Description of the Item Category
Responsibility Responsibilities that radiation oncologists, gynecological oncologists, and oncology nurses have
regarding their patients’ sexual rehabilitation (eg, providing practical advice on how to cope
with sexual problems)
Target population Specific patient groups that should receive information regarding sexual rehabilitation using
vaginal dilators
Vaginal dilator Type of dilator that is best advised
Rationale The rationale that health care providers should use to advise the use of dilators
Content instructions Information and instructions that should be provided regarding the use of vaginal dilators and
sexual intercourse during sexual rehabilitation
Information provision Type of health care provider that should provide information regarding sexual rehabilitation and
vaginal dilator use, the time interval at which information should be provided, and the
informational resource that should be used
Patient support Type of health care provider that should provide sexual health support during rehabilitation and
dilator use and to what extent sexual health support should be given by a radiation oncologist,
gynecological oncologist, or oncology nurse
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part of their responsibility to evaluate their patients’ sexual
functioning (n = 10; 100% agreed; IQR, 1.00). The radiation
oncologists almost reached the same consensus (n = 8; 80%
agreed; IQR, 1.25). However, the oncology nurses disagreed
(IQR, 4.50) about whether this is their responsibility.
The panel did uniformly agree that it is important to
give patients advice on how to cope with fear for sexual
contact after treatment and, if necessary, to refer patients to a
sexologist after treatment with RT for gynecological cancers.
Furthermore, participants agreed that all sexually active cer-
vical and vaginal cancer patients with a partner, younger than
70 years, should always be informed about sexual rehabili-
tation using vaginal dilators. Regarding the use of vaginal
dilators, participants thought that dilators should be pre-
scribed with the rationale that regular dilator use prevents the
formation of vaginal adhesions and stenosis, and keeps the
vagina accessible for penetration in the future. Vaginal di-
lators should be used together with lubricants. Furthermore, it
was thought that the frequency of vaginal dilator use could be
reduced in case the patient has resumed sexual intercourse.
Health care providers, instead of the patient herself, should
initiate the provision of information and patient support on
this topic during follow-up appointments after treatment.
Monitoring of dilator use and discussion of barriers or
problems with its use should take place during each follow-up
appointment.
Consensus Round 2
The panel reached consensus on 31 of 52 items in
round 2 (60%; Supplemental Digital Content 1) with an equal
degree of consensus between the 3 specialisms. After round 2,
14 items were formulated differently based on comments
by participants. In addition, 1 item was removed from the
questionnaire because this question was less specific than
another item addressing the same subject.
The participants agreed that it is part of their respon-
sibility to provide practical advice on how to cope with sexual
problems. Patients treated with brachytherapy in combination
with external beam RT (or on individual indications) and also
patients without a current partner, especially those with cer-
vical and vaginal cancer, should be informed about sexual
rehabilitation using vaginal dilators. Patients may start having
sexual intercourse 2 to 4 weeks after treatment completion.
Most participants also recommended use of dilators with the
rationale that dilator use makes future vaginal examinations
during follow-up appointments less inconvenient. Two par-
ticipants added, however, that this is not an argument to
prescribe vaginal dilators, in case a patient would have no
other reason to use dilators. Furthermore, participants agreed
that it is not desirable to recommend use of vaginal dilators
only after vaginal adhesions have been established. According
to the panel, the most suitable dilators were commercially
available plastic dilator sets. Vaginal dilators should be used
2 to 3 times a week during 9 to 12 months after treatment.
It could help to move and rotate the dilator around when
inserted.Thepanel agreed that gradually using a bigger cylinder
circumference in time is important.
An introduction with general information about vagi-
nal dilation should be given before the start of RT. There was
consensus that the oncology nurse is the most appropriate
professional to provide more extensive information and pa-
tient support during sexual rehabilitation and the use of
dilators. However, in each cancer center, all gynecological
oncology experts should be involved in multidisciplinary
care and provide patient information, counseling, and sup-
port during sexual rehabilitation.
Consensus Round 3
Consensus was reached for 8 of 21 items in round 3
(38%; Supplemental Digital Content 1), and the degree of
consensus was equal between the 3 specialisms. The panel
agreed that it is best if radiation oncologists give the first
introduction and information about vaginal dilation. More
extensive information should be provided during the first
posttreatment follow-up appointment. According to the pa-
nel, the use of vaginal dilators can also help patients to re-
duce fear of bodily changes and fear of sexual activity. If
preferred, patients can use a vibrator as a vaginal dilator. Fur-
thermore, health care providers should counsel patients on
which type(s) of dilator they can use, but the patient ulti-
mately decides. To prevent adhesions, inserting the vaginal
dilator for 1 to 3 minutes was thought to be sufficient. Table 2
summarizes the results and consensus-based recommenda-
tions of the study.
No Consensus
No agreement was reached on whether or not to pro-
vide standard information about sexual rehabilitation using
vaginal dilators to vulvar and endometrial cancer patients,
FIGURE 1. Delphi panel characteristics.
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TABLE 2. Summary of the consensus-based recommendations described per category
Category Consensus
Responsibility &Health care providers should give patients simple sexological advice,* such as how to
cope with fear for sexual contact after treatment.†
&It is desirable to refer patients to a sexologist in case simple sexological advice does not suffice.†
Target population Patients should be informed about vaginal dilation in case they were:
&Sexually active before treatment† (independent of whether they have a partner*†)
&Treated with RT for cervical† or vaginal cancer†
&Treated with vaginal brachytherapy in combination with external beam RT
(or on individual indications)*
Vaginal dilator &Health care providers should advise on which type of dilator should be used, but the patient
ultimately decides.‡
&The most often recommended type of dilator are commercially available plastic dilator sets.*
&Patients may use a vibrator if preferred.‡
&The circumference of a dilator is important during usage.†
Rationale The rationale that health care providers use to prescribe vaginal dilation should contain
that dilation:
&Prevents the formation of vaginal adhesions†
&Keeps the vagina accessible for any form of penetration in the future†
&Also makes future vaginal examination (during follow-up appointments) more convenient*
&Can be useful to help reduce fear for bodily changes and sexual activity‡
&Vaginal dilation should start preventively† and not only in case of established adhesion.*
Content instructions &Plastic cylinders, vibrators, dildos, and fingers should be inserted at least 1 to 3 minutes,
2 to 3 times a week,* and during 9 to 12 months after treatment.*
&Vaseline tampons (tampons covered in Vaseline) should be inserted overnight,*
2 to 3 times a week,* and during at least 9 to 12 months after treatment.‡
&Lubricants should be advised together with vaginal dilators.†
&Gradually using a bigger cylinder circumference in time is important.*
&It is best to insert vaginal dilators as deep as possible,† in a position determined by the patient
herself,† and to move the dilator around when inserted.*
&Patients should consult their health care provider in case of new complaints about pain†
or lasting loss of blood.†
&Whether or not the partner is actively involved should depend on the patients’ needs.‡
&The frequency of use can be lowered in case the patient also has successful sexual intercourse.†
&Patients may start having sexual intercourse 2 to 4 weeks after treatment.*
Information provision &The health care center decides which health care provider is responsible for informing
patients about vaginal dilation.*
&The radiation oncologist‡ should provide the first introduction‡ before RT.*
&The oncology nurse should provide the more extensive information* during the first follow-up
appointment.‡
&The health care provider should initiate information provision, at least face-to-face,†
even if the patient does not begin to talk about it.†
&The patients’ partners should be involved.*
&The availability of an informational brochure† and Web site† is desirable.
(Continued on next page)
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patients older than 70 years, and patients who were not sex-
ually active before treatment (Supplemental Digital Con-
tent 2, http://links.lww.com/IGC/A231). Some participants
recommended tailoring the information for these patient
groups depending on the specific type(s) of treatment, age,
wish to retain sexual activity, and personal and medical sit-
uation. Some participants commented to inform every pa-
tient about sexuality and vaginal dilator use after treatment
with regard to possible needs in the future. Furthermore,
participants did not agree on whether dilation should be
started between 2 and 4 weeks after RT (n = 20; 67%) or later.
It was commented that it is important for the vaginal mucosa
to have healed before dilation is started, which often takes
4 weeks after completion of RT.
DISCUSSION
A 3-round online Delphi study was conducted to as-
sess the content and procedures of patient information pro-
vision and support regarding sexual rehabilitation and vaginal
dilator use after RT for gynecological cancer. The study was
conducted among 30 gynecologic oncology experts from 12
gynecological cancer centers. The panel equally represented
radiation oncologists, gynecologic oncologists, and special-
ized oncology nurses involved and experienced in counseling
and the follow-up of gynecological cancer patients after RT.
All participants completed the 3 rounds. The degree to which
consensus was reached was equal between the 3 professional
groups. Previously, no specific recommendations could be
made regarding the content and procedures of information
provision and support during sexual rehabilitation and vagi-
nal dilator use.16,22,23 This study offers a clear consensus
on these topics.
Consensus was reached that information about sexual
rehabilitation and vaginal dilator use should be given to all
sexually active cervical and vaginal cancer patients younger
than 70 years. Moreover, comments by the participants made
clear that vulvar and endometrial cancer patients, patients
older than 70 years, and patients who were not sexually
active before treatment should receive care tailored to their
needs. The participants also agreed that radiation oncolo-
gists should initiate and provide information about sexual
adverse effects of RT, rehabilitation, and preventive measures
including vaginal dilator use before treatment. In addition,
in line with previous suggestions,30 more extensive dedi-
cated psychological and practical support should preferably
be initiated and given by specifically trained oncology nurses.
Although in this study, no clear consensus was reached
on the best time to start dilator use, most participants recom-
mended to start between 2 and 4 weeks after completion of
RT (n = 20; 67%) or as soon as the vaginal mucosa is healed
(which is usually around 4 weeks). This was also the most
commonly cited time interval in the studies of White and
Faithfull22 and Lancaster.23 Furthermore, there was consensus
that the frequency with which dilators should be used, prefer-
ably 2 to 3 times a week, could be reduced in case the patient
has resumed sexual intercourse.
The panel agreed that it is important to gradually use
a bigger cylinder circumference in time. Participants in this
study also agreed that each dilator should be inserted during
1 to 3 minutes, which is in contrast to previous recommen-
dations of 5 to 10 minutes.16,22,23 Furthermore, the panel
agreed that it is best to perform dilation for 9 to 12 months,
whereas in previous studies, about half of the respondents
recommended indefinite use.22,23 However, in contrast to the
aforementioned survey studies,22,23 this present study con-
ducted the Delphi method among a heterogeneous panel.
Therefore, the results of this study were thought to reflect
the opinion of all professionals involved in counseling and
the follow-up of gynecological cancer patients after RT.
Adapting items for the next round in the Delphi study
obviously poses a risk of a self-fulfilling prophecy.25 How-
ever, the items concerned were adapted using experts’ com-
ments in a systematic way, and all the adapted items were
pilot-tested on comprehensibility again among 5 experienced
researchers in the field. The professionals that participated in
this study were expected to be potential users of the find-
ings and, consequently, were thought to form the most useful
TABLE 2. (Continued)
Category Consensus
Patient support &The health care center decides which health care provider is responsible for supporting
patients during sexual rehabilitation.*
&Monitoring vaginal dilator use should always take place during follow-up appointments.†
&The oncology nurse should provide psychological and practical patient support
during sexual rehabilitation.*
&The health care provider should initiate providing patient support even if the patient does
not take the initiative.†
&Extra consultations to support the patient should be possible.*
&Extra referral possibilities† for patients with sexual problems and more training possibilities
in assessing sexual complaints* are desirable.
*Consensus reached in round 2.
†Consensus reached in round 1.
‡Consensus reached in round 3.
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expert panel. In a separate in-depth interview study, the per-
spective of gynecological cancer patients on sexual rehabili-
tation and dilator use after pelvic RTwill be investigated. The
patient’s perspective on this topic is required to be able to im-
prove patient care because it is expected that these patients
have additional needs. For example, participants in this study
considered the rigid plastic dilator sets as the most suitable
type of dilator to prescribe, whereas patients might have pre-
ferred a softer flexible dilator.21 The efficacy of regular dila-
tor use can only be assessed in a randomized controlled trial
if there is a standardized procedure of sexual rehabilitation
and vaginal dilator use. Using the Delphi method, a common
consensus was created out of the available expertise. It is
therefore important to further investigate whether the results
of this study are generally applicable in clinical practice and
support patients during their sexual rehabilitation after pelvic
RT before final policy decisions can be made.
In conclusion, the results of this study offer clear
consensus-based recommendations for the education and
support of gynecological cancer patients treated with pelvic
RT during sexual rehabilitation and vaginal dilator use. Based
on these results, an intervention has been developed and is
currently pilot-tested in which patients receive support during
sexual rehabilitation and vaginal dilator use after pelvic RT.
This study was a first step toward the improvement of gy-
necological cancer patient support during their sexual reha-
bilitation after pelvic RT.
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